Scientists with Oxford University say a CCP virus vaccine candidate they’re developing could be available by the fall of 2020.
Most groups working on vaccines have pinpointed early 2021 as the earliest they'll be available for distribution.
After phase one, which involves injecting 510 volunteers with the vaccine and 510 others with a control vaccine, researchers plan on extending the trial to older groups of people before launching phase three with 5,000 volunteers aged 19 and older.
They added: “These best-case timeframes are highly ambitious and subject to change.”
Scientists from the group told multiple media outlets they foresee the vaccine being available as early as September.
One reason for the quicker timeline: manufacturing facilities are planning to start producing the vaccine even as it’s still being tested.
Massachusetts-based MilliporeSigma said earlier this month that it laid a foundation with the Jenner Institute for large-scale production of the vaccine candidate, a process that typically takes six months to a year. HALIX B.V. in the Netherlands is also scaling up manufacturing that will take place alongside early trials. And the Serum Institute of India plans to produce 4 to 5 million doses per month even before the trials are fully complete.
Up to 60 million doses could be produced this year, Poonawalla said.
Human trials of the candidate in India are planned to start in May.